133 related articles for article (PubMed ID: 2180231)
1. Live Shigella flexneri 2a and Shigella sonnei I vaccine candidate strains with two attenuating markers. II. Preliminary results of vaccination of adult volunteers and children aged 2-17 years.
Dentchev V; Marinova S; Vassilev T; Bratoyeva M; Linde K
Vaccine; 1990 Feb; 8(1):30-4. PubMed ID: 2180231
[TBL] [Abstract][Full Text] [Related]
2. Shigella flexneri 2a and sonnei I vaccine with two attenuating markers: construction, tolerability and immunogenicity in 143 children aged 3-17 years.
Linde K; Randhagen B; Beer J; Dentchev V; Marinova S; Vassilev T; Bratoyeva M
Vaccine; 1993; 11(2):197-9. PubMed ID: 8438618
[TBL] [Abstract][Full Text] [Related]
3. Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124.
Li A; Cam PD; Islam D; Minh NB; Huan PT; Rong ZC; Karlsson K; Lindberg G; Lindberg AA
J Infect; 1994 Jan; 28(1):11-23. PubMed ID: 8163828
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers.
Li A; Kärnell A; Huan PT; Cam PD; Minh NB; Trâm LN; Quy NP; Trach DD; Karlsson K; Lindberg G
Vaccine; 1993; 11(2):180-9. PubMed ID: 8438616
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM
Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
[TBL] [Abstract][Full Text] [Related]
7. [Local Immune response in rabbits following enteral immunization with live attenuated bacterial Enterobacteriaceae vaccines].
Dentschev W; Marinova S; Sumerska T; Nenkov P; Koitschev T; Trifonowa A
Arch Exp Veterinarmed; 1980; 34(1):9-13. PubMed ID: 6998404
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers.
Kärnell A; Li A; Zhao CR; Karlsson K; Nguyen BM; Lindberg AA
Vaccine; 1995 Jan; 13(1):88-99. PubMed ID: 7762285
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.
Kotloff KL; Losonsky GA; Nataro JP; Wasserman SS; Hale TL; Taylor DN; Newland JW; Sadoff JC; Formal SB; Levine MM
Vaccine; 1995 Apr; 13(5):495-502. PubMed ID: 7639017
[TBL] [Abstract][Full Text] [Related]
11. Potential Shigella flexneri 2a and Shigella sonnei I live vaccinal strains. Characterization of immunogenicity in animal models.
Denchev V; Sumerska T; Marinova S; Vassilev T; Panova I; Linde K
Acta Microbiol Hung; 1990; 37(4):359-66. PubMed ID: 2099082
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
[TBL] [Abstract][Full Text] [Related]
13. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
Passwell JH; Ashkenazi S; Banet-Levi Y; Ramon-Saraf R; Farzam N; Lerner-Geva L; Even-Nir H; Yerushalmi B; Chu C; Shiloach J; Robbins JB; Schneerson R;
Vaccine; 2010 Mar; 28(10):2231-2235. PubMed ID: 20056180
[TBL] [Abstract][Full Text] [Related]
14. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose.
Mel DM; Arsic BL; Radovanovic ML; Litvinjenko SA
Acta Microbiol Acad Sci Hung; 1974; 21(1-2):109-14. PubMed ID: 4613128
[No Abstract] [Full Text] [Related]
15. Live Shigella flexneri 2a and Shigella sonnei I vaccine candidate strains with two attenuating markers. I. Construction of vaccine candidate strains with retained invasiveness but reduced intracellular multiplication.
Linde K; Dentchev V; Bondarenko V; Marinova S; Randhagen B; Bratoyeva M; Tsvetanov Y; Romanova Y
Vaccine; 1990 Feb; 8(1):25-9. PubMed ID: 2180230
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers.
Li A; Pál T; Forsum U; Lindberg AA
Vaccine; 1992; 10(6):395-404. PubMed ID: 1598788
[TBL] [Abstract][Full Text] [Related]
17. Technological aspect of the production of live dysentery vaccines for oral administration.
Denchev V; Nenkov P; Vitanov T; Sumerska T; Marinova S; Vassilev T; Panova I; Bratoeva M; Linde K
Acta Microbiol Hung; 1991; 38(2):121-6. PubMed ID: 1805499
[TBL] [Abstract][Full Text] [Related]
18. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of WRSS1, a
Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM
Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051
[No Abstract] [Full Text] [Related]
20. Outpatient studies of the safety and immunogenicity of an auxotrophic Escherichia coli K-12-Shigella flexneri 2a hybrid vaccine candidate, EcSf2a-2.
Taylor DN; Phillip DF; Zapor M; Trofa A; Van de Verg L; Hartman A; Bendiuk N; Newland JW; Formal SB; Sadoff JC
Vaccine; 1994 May; 12(6):565-8. PubMed ID: 8036831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
